Russia registers drug against all COVID-19 strains

12 January 2022

A new drug that could be recommended for the treatment of all strains of coronavirus has recently been registered in Russia. The new drug is known as MIR-19, and its supplies to Russian hospitals will begin already soon.

MIR-19 was developed by the Russian Federal Medical and Biological Agency (FMBA). It is available in the form of a liquid for inhalation.

As head of the FMBA Veronika Skvortsova said in an interview with Russia 24 TV channel, the drug is highly effective, and the FMBA plans to create two more types of drug in the form of a nasal spray. The nasal version of the "Mira-19" will be designed for prevention of COVID-19, as it will protect people who have come into contact with patients with COVID-19.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK